Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Characteristics of SOD1G93A rats used in the post-paralysis masitinib trial

From: Post-paralysis tyrosine kinase inhibition with masitinib abrogates neuroinflammation and slows disease progression in inherited amyotrophic lateral sclerosis

  Vehicle Masitinib (>day 1) Masitinib (>day 7)
Age at onset (days) 187 ± 15 182 ± 25 198 ± 14
Weight at onset (g) 315 ± 56 306 ± 16 323 ± 71
Weight at end-stage (g) 235 ± 13 214 ± 50 211 ± 50
Survival range (days) 174–234 177–249 201–246
  1. The table shows characteristics of the consolidated studies for rats treated with vehicle, masitinib starting 1 (>day 1) and 7 (>day 7) days after paralysis onset. Age and weight values are expressed as mean ± SD. Survival range indicates the age of rats at the time animals reached end-stage of paralysis
Back to article page